Financial PerformanceThe stock is currently trading at a substantial discount to its cash position, which is viewed as fair value, consistent with other biotech companies with similar uncertainties.
Operational CostsA one-time lease termination increased Q1 operating loss, although cost-cutting measures are in place with new cash burn guidance.
Strategic DecisionsGeneration is deprioritizing development of iqDNA, leading to a target price reduction after removing value attributed to the iqDNA platform.